These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 26024723)
1. Acceptance Probability (P a) Analysis for Process Validation Lifecycle Stages. Alsmeyer D; Pazhayattil A; Chen S; Munaretto F; Hye M; Sanghvi P AAPS PharmSciTech; 2016 Apr; 17(2):516-22. PubMed ID: 26024723 [TBL] [Abstract][Full Text] [Related]
2. Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products. Tsong Y; Dong X; Shen M; Lostritto RT J Biopharm Stat; 2015; 25(2):328-38. PubMed ID: 25357132 [TBL] [Abstract][Full Text] [Related]
3. Stage 2 Process Performance Qualification (PPQ): a Scientific Approach to Determine the Number of PPQ Batches. Pazhayattil A; Alsmeyer D; Chen S; Hye M; Ingram M; Sanghvi P AAPS PharmSciTech; 2016 Aug; 17(4):829-33. PubMed ID: 26349690 [TBL] [Abstract][Full Text] [Related]
4. Probability of passing dissolution acceptance criteria for an immediate release tablet. Dumont ML; Berry MR; Nickerson B J Pharm Biomed Anal; 2007 May; 44(1):79-84. PubMed ID: 17379465 [TBL] [Abstract][Full Text] [Related]
5. Using tolerance intervals for assessment of pharmaceutical quality. Dong X; Tsong Y; Shen M; Zhong J J Biopharm Stat; 2015; 25(2):317-27. PubMed ID: 25356617 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of blend uniformity and content uniformity based on 2003 stratified sampling guidance and 1999 blend uniformity analysis guidance: product A. Howard-Sparks M; Gawlikowski A; PDA J Pharm Sci Technol; 2004; 58(4):222-30. PubMed ID: 15368992 [TBL] [Abstract][Full Text] [Related]
7. Estimation of the probability of passing the USP dissolution test. Wang H J Biopharm Stat; 2007; 17(3):407-13. PubMed ID: 17479390 [TBL] [Abstract][Full Text] [Related]
16. Content uniformity acceptance limit for a validation batch--suppositories, transdermal systems, and inhalations. Senderak ET Drug Dev Ind Pharm; 2009 Jun; 35(6):735-7. PubMed ID: 19514989 [TBL] [Abstract][Full Text] [Related]
17. Excipient variability and its impact on dosage form functionality. Dave VS; Saoji SD; Raut NA; Haware RV J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249 [TBL] [Abstract][Full Text] [Related]
18. Validation of analytical methods involved in dissolution assays: acceptance limits and decision methodologies. Rozet E; Ziemons E; Marini RD; Boulanger B; Hubert P Anal Chim Acta; 2012 Nov; 751():44-51. PubMed ID: 23084050 [TBL] [Abstract][Full Text] [Related]
19. Application of the quality by design approach to the drug substance manufacturing process of an Fc fusion protein: towards a global multi-step design space. Eon-duval A; Valax P; Solacroup T; Broly H; Gleixner R; Strat CL; Sutter J J Pharm Sci; 2012 Oct; 101(10):3604-18. PubMed ID: 22821774 [TBL] [Abstract][Full Text] [Related]
20. A case study: application of statistical process control tool for determining process capability and sigma level. Chopra V; Bairagi M; Trivedi P; Nagar M PDA J Pharm Sci Technol; 2012; 66(2):98-115. PubMed ID: 22492596 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]